Who Supplies Semaglutide to India from NETHERLANDS

To import finished pharmaceutical formulations containing Semaglutide into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the importer and the product be registered. The importer must obtain an Import License from the Directorate General of Foreign Trade (DGFT), and the product requires CDSCO approval, typically involving the submission of Form CT-20/40/41. The registration process includes providing stability data (ICH Zone IV), a Certificate of Pharmaceutical Product (CoPP), and a No Objection Certificate (NOC) from the manufacturer. The timeline for import drug registration varies but generally takes several months, depending on the completeness of the application and regulatory review. For Semaglutide formulations under HS Code 30049099, specific requirements include demonstrating compliance with Indian Pharmacopoeia standards and providing detailed product dossiers.

Imported Semaglutide formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure product efficacy and safety. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products. If a batch fails quality testing, it may be subject to rejection, re-exportation, or destruction, depending on the severity of the non-compliance.

Between 2024 and 2026, the CDSCO introduced stricter regulations for imported medicines, including mandatory import registration and licensing to prevent the sale of unapproved or illegal drugs in the Indian market. The Production-Linked Incentive (PLI) scheme, implemented to boost domestic manufacturing, has impacted the import of finished formulations, encouraging self-reliance and reducing dependency on imports. Bilateral agreements between India and the Netherlands have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) and streamlined approval processes for pharmaceutical imports.

India imports finished Semaglutide formulations primarily due to the unavailability of certain patented or branded formulations domestically. Specific dosage forms and strengths not produced locally necessitate imports to meet patient needs. The domestic capacity for manufacturing Semaglutide formulations is limited, leading to a reliance on imports to fulfill market demand. The market size for Semaglutide formulations in India is substantial, with a growing number of patients requiring treatment for diabetes and obesity.

The Basic Customs Duty (BCD) for Semaglutide formulations under HS Code 30049099 is 10%. The Social Welfare Surcharge (SWS) is 10% of the BCD, resulting in an additional 1% duty. Integrated Goods and Services Tax (IGST) is applicable, with rates varying based on the product classification. There are no exemptions or preferential rates for imports from the Netherlands. The total landed duty percentage combines these components, affecting the final cost of imported Semaglutide formulations.

India sources Semaglutide formulations from the Netherlands due to the availability of patented formulations and specialized dosage forms not produced domestically. Dutch manufacturers are known for high-quality standards and compliance with international regulatory requirements, ensuring product safety and efficacy. While other suppliers like China, Germany, and the United States also export Semaglutide formulations to India, the Netherlands maintains a competitive edge through consistent quality and reliable supply chains. The Netherlands holds a significant share in the Indian market for Semaglutide imports, reflecting its strong position as a supplier.

India imports Semaglutide formulations from the Netherlands due to the availability of patented formulations and specialized dosage forms not produced domestically. Dutch manufacturers offer high-quality products that meet international standards, ensuring safety and efficacy. The Netherlands's strong regulatory compliance and reliable supply chains make it a preferred source for these formulations.

Compared to other origins like China, Germany, and the United States, the Netherlands offers competitive advantages in terms of product quality, regulatory compliance, and supply chain reliability. Dutch manufacturers adhere to stringent quality control measures, ensuring that Semaglutide formulations meet the required standards. While other countries may offer lower prices, the Netherlands's consistent quality and adherence to international regulations provide a unique advantage for Indian importers.

Indian importers face several supply chain risks when sourcing Semaglutide formulations from the Netherlands, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, closely monitoring currency exchange rates, staying updated on regulatory changes, and establishing contingency plans for potential shipping disruptions. Past shortages have been minimal, but proactive risk management is essential to ensure a steady supply.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Payment (DA), or Documents Against Acceptance (DP), to manage financial exposure.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts and inventory management.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits and assessments, to ensure compliance with quality and regulatory standards.